<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35373863</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2796</ISSN><JournalIssue CitedMedium="Internet"><Volume>292</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of internal medicine</Title><ISOAbbreviation>J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Impact of the post-COVID-19 condition on health care after the first disease wave in Lombardy.</ArticleTitle><Pagination><StartPage>450</StartPage><EndPage>462</EndPage><MedlinePgn>450-462</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.13493</ELocationID><Abstract><AbstractText Label="BACKGROUND">Lombardy was affected in the early months of 2020 by the SARS-CoV-2 pandemic with very high morbidity and mortality. The post-COVID-19 condition and related public health burden are scarcely known.</AbstractText><AbstractText Label="SETTING AND DESIGN">Using the regional population administrative database including all the 48,932 individuals who survived COVID-19 and became polymerase-chain-reaction negative for SARS-CoV-2 by 31 May 2020, incident mortality, rehospitalizations, attendances to hospital emergency room, and outpatient medical visits were evaluated over a mid-term period of 6 months in 20,521 individuals managed at home, 26,016 hospitalized in medical wards, and 1611 in intensive care units (ICUs). These data were also evaluated in the corresponding period of 2019, when the region was not yet affected by the pandemic. Other indicators and proxies of the health-care burden related to the post-COVID condition were also evaluated.</AbstractText><AbstractText Label="MAIN RESULTS">In individuals previously admitted to the ICU and medical wards, rehospitalizations, attendances to hospital emergency rooms, and out-patient medical visits were much more frequent in the 6-month period after SARS-CoV-2 negativization than in the same prepandemic period. Performances of spirometry increased more than 50-fold, chest CT scans 32-fold in ICU-admitted cases and 5.5-fold in non-ICU cases, and electrocardiography 5.6-fold in ICU cases and twofold in non-ICU cases. Use of drugs and biochemical tests increased in all cases.</AbstractText><AbstractText Label="CONCLUSIONS">These results provide a real-life picture of the post-COVID condition and of its effects on the increased consumption of health-care resources, considered proxies of comorbidities.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Journal of Internal Medicine published by John Wiley &amp; Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mannucci</LastName><ForeName>Pier M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7813-0572</Identifier><AffiliationInfo><Affiliation>Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tettamanti</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Avanzo</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galbussera</LastName><ForeName>Alessia A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remuzzi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortino</LastName><ForeName>Ida</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Direzione Generale Welfare, Regione Lombardia, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leoni</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Direzione Generale Welfare, Regione Lombardia, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences and Community Health, Universit&#xe0; di Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Internal Medicine, Multimedica IRCSS, Milano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intern Med</MedlineTA><NlmUniqueID>8904841</NlmUniqueID><ISSNLinking>0954-6820</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lombardy region</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">administrative database</Keyword><Keyword MajorTopicYN="N">clinical sequalae</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">polypharmacy</Keyword><Keyword MajorTopicYN="N">population study</Keyword></KeywordList><CoiStatement>All the authors declare no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>4</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35373863</ArticleId><ArticleId IdType="pmc">PMC9115275</ArticleId><ArticleId IdType="doi">10.1111/joim.13493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Casti E, Adobati F, Negri I. Mapping the epidemic: a systemic geography of COVID&#x2010;19 in Italy, volume 9. https://www.sciencedirect.com/bookseries/modern&#x2010;cartography&#x2010;series/vol/9/suppl/C (2021). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
ESRI
. COVID&#x2010;19 situazione Italia. https://opendatadpc.maps.arcgis.com/apps/dashboards/b0c68bce2cce478eaac82fe38d4138b1 (2022). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)
. COVID&#x2010;19 dashboard. https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6 (2022). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
Regione Lombardia
. Dashboard covid&#x2010;19. https://www.regione.lombardia.it/wps/portal/istituzionale/HP/servizi&#x2010;e&#x2010;informazioni/cittadini/salute&#x2010;e&#x2010;prevenzione/coronavirus/dashboard&#x2010;covid19 (2022). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
Consolandi E. Chapter 1.3&#x2014;Evolution and intensity of infection in Lombardy. In: Casti E, Adobati F, Negri I, editors. Mapping the epidemic: a systemic geography of COVID&#x2010;19 in Italy, volume 9. https://www.sciencedirect.com/science/article/abs/pii/B9780323910613000089 (2021). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
Negri I, Mazzoleni M. Chapter 2.2&#x2014;Mortality and severity of infection in Lombardy. In: Casti E, Adobati F, Negri I, editors. Mapping the epidemic: a systemic geography of COVID&#x2010;19 in Italy, volume 9. https://www.sciencedirect.com/science/article/abs/pii/B9780323910613000132 (2021). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
Brambilla A. Chapter 5.1&#x2014;Epidemic onset and population and production density of outbreaks in Lombardy. In: Casti E, Adobati F, Negri I, editors. Mapping the epidemic: a systemic geography of COVID&#x2010;19 in Italy, volume 9. https://www.sciencedirect.com/science/article/abs/pii/B9780323910613000077 (2021). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
Adobati F, Comi E, Ghisalberti A. Chapter 6.1&#x2014;Public policies for epidemic containment in Italy. https://www.sciencedirect.com/science/article/pii/B978032391061300020X (2021). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
Adobati F, Comi E, Ghisalberti A. Chapter 6.2&#x2014;Containment measures in relation to the trend of infection in Italy. In: Casti E, Adobati F, Negri I, editors. Mapping the epidemic: a systemic geography of COVID&#x2010;19 in Italy, volume 9. https://www.sciencedirect.com/science/article/pii/B9780323910613000041 (2021). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>Rubin R. As their numbers grow, COVID&#x2010;19 &#x201c;long haulers&#x201d; stump experts. JAMA. 2020;324:1381&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32965460</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. The lasting misery of coronavirus long&#x2010;haulers. Nature. 2020;585:339&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">32929257</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli Against COVID&#x2010;19 Post&#x2010;Acute Care Study Group . Persistent symptoms in patients after acute COVID&#x2010;19. JAMA. 2020;324:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid&#x2010;19: what do we know about &#x201c;long covid&#x201d;? BMJ. 2020;370:m2815.</Citation><ArticleIdList><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et&#xa0;al. Post&#x2010;covid syndrome in individuals admitted to hospital with covid&#x2010;19: retrospective cohort study. BMJ. 2021;372:n693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et&#xa0;al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post&#x2010;COVID&#x2010;19 symptom burden: what is long&#x2010;COVID and how should we manage it? Lung. 2021;199:113&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyengar KP, Jain VK, Vaishya R, Ish P. Long COVID&#x2010;19: an emerging pandemic in itself. Adv Respir Med. 2021;89:234&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33966266</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et&#xa0;al. TLC Study Group . Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114:428&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid&#x2010;mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin&#x2010;angiotensin&#x2010;aldosterone system blockers and the risk of Covid&#x2010;19. N Engl J Med. 2020;382:2431&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206933</ArticleId><ArticleId IdType="pubmed">32356627</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO Collaborating Centre for Drug Statistics Methodology
, Norwegian Institute of Public Health
. ATC/DDD index 2021. https://www.whocc.no/atc_ddd_index/ (2021). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
CDC NCHS
. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD&#x2010;9&#x2010;CM). https://www.cdc.gov/nchs/icd/icd9cm.htm (2021). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>
CDC NCHS
. CDC announces approval of ICD&#x2010;10 code for post&#x2010;acute sequelae of COVID&#x2010;19. https://www.cdc.gov/nchs/icd/icd10cm.htm (2022). Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;Las&#x2010;Pe&#xf1;as C, Palacios&#x2010;Ce&#xf1;a D, G&#xf3;mez&#x2010;Mayordomo V, Florencio LL, Cuadrado ML, Plaza&#x2010;Manzano G, et&#xa0;al. Prevalence of post&#x2010;COVID&#x2010;19 symptoms in hospitalized and non&#x2010;hospitalized COVID&#x2010;19 survivors: a systematic review and meta&#x2010;analysis. Eur J Intern Med. 2021;92:55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker HR, Gulea C, Koteci A, Kallis C, Morgan AD, Iwundu C, et&#xa0;al. GP consultation rates for sequelae after acute covid&#x2010;19 in patients managed in the community or hospital in the UK: population based study. BMJ. 2021;375:e065834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715128</ArticleId><ArticleId IdType="pubmed">34965929</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et&#xa0;al. Hypercoagulability of COVID&#x2010;19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18:1738&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari S, Ripamonti L, Marveggio P, Mannucci PM. Long COVID: a patient perspective. Eur J Intern Med. 2022;95:104&#x2013;5. 10.1016/j.ejim.2021.10.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.10.023</ArticleId><ArticleId IdType="pmc">PMC8553650</ArticleId><ArticleId IdType="pubmed">34756631</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin C, Luteijn M, Letton W, Robertson J, McDonald S. A model framework for projecting the prevalence and impact of Long&#x2010;COVID in the UK. PLoS One. 2021;16:e0260843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639065</ArticleId><ArticleId IdType="pubmed">34855874</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et&#xa0;al. COVID&#x2010;19 Lombardy ICU Network . Baseline characteristics and outcomes of 1591 patients infected with SARS&#x2010;CoV&#x2010;2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323:1574&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. Long COVID's long R&amp;D agenda. Nat Rev Drug Discov. 2021;20:329&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33879882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et&#xa0;al. Developing services for long COVID: lessons from a study of wounded healers. Clin Med. 2021;21:160. 10.7861/clinmed.err.21.2</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.err.21.2</ArticleId><ArticleId IdType="pmc">PMC8002785</ArticleId><ArticleId IdType="pubmed">33762402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangrillo A, Belletti A, Palumbo D, Calvi MR, Guzzo F, Fominskiy EV, et&#xa0;al. One&#x2010;year multidisciplinary follow&#x2010;up of patients with COVID&#x2010;19 requiring invasive mechanical ventilation. J Cardiothorac Vasc Anesth. 2022;36:1354&#x2013;63. 10.1053/j.jvca.2021.11.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2021.11.032</ArticleId><ArticleId IdType="pmc">PMC8626145</ArticleId><ArticleId IdType="pubmed">34973891</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker AJ, Humbir A, Tiwary P, Mishra M, Shanmugam M, Bhatia K, et&#xa0;al. Recovery after critical illness in COVID&#x2010;19 ICU survivors. Br J Anaesth. 2021;126:e217&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972647</ArticleId><ArticleId IdType="pubmed">33812669</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamberini L, Mazzoli CA, Sintonen H, Colombo D, Scaramuzzo G, Allegri D, et&#xa0;al. Quality of life of COVID&#x2010;19 critically ill survivors after ICU discharge: 90 days follow&#x2010;up. Qual Life Res. 2021;30:2805&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113006</ArticleId><ArticleId IdType="pubmed">33977415</ArticleId></ArticleIdList></Reference><Reference><Citation>Taboada M, Moreno E, Cari&#xf1;ena A, Rey T, Pita&#x2010;Romero R, Leal S, et&#xa0;al. Quality of life, functional status, and persistent symptoms after intensive care of COVID&#x2010;19 patients. Br J Anaesth. 2021;126:e110&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833644</ArticleId><ArticleId IdType="pubmed">33413976</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>